Several H-2 defined cell lines were examined for their ability to support infection and replication of Japanese encephalitis virus (JEV) before their use in in vitro and in viro stimulation protocols for generating cytotoxic T lymphocytes (CTLs) against JEV. Among 11 different cell lines tested, two H-2 ~ macrophage tumour lines (P388D1, RAW 264.7), an H-2 d hybridoma (Sp2/0), an H-2KkD d neuroblastoma (Neuro 2a), and H-2 k fibroblast cell line (L929) were found to support JEV infection and replication. These cell lines were used to generate anti-JEV CTLs by using in vivo immunization followed by in vitro stimulation of BALB/c mice. We observed that not only syngeneic and allogeneic infected cells but also JEV-infected xenogeneic cells could prime BALB/c mice for the generation of JEV-specific CTLs upon subsequent in vitro stimulation of splenocytes with JEVinfected syngeneic cells. Although infected xenogeneic cells were used for immunization, the anti-JEV effectors that were generated lysed infected syngeneic targets but not JEV-infected xenogeneic or allogeneic target cells in a 5 h 51Cr release assay. These anti-JEV effectors recognized syngeneic target cells infected with West Nile virus to a lesser extent and were shown to be Lyt-2.2 + T cells. The results of unlabelled cold target competition studies suggested alterations in the cell surface expression of viral antigenic determinants recognized by these CTLs. We further demonstrate that the JEVspecific CTLs generated could virtually block the release of infectious virus particles from infected P388D1 and Neuro 2a cells in vitro.
Introduction
Japanese encephalitis virus (JEV) is a positive-stranded RNA virus which belongs to the flavivirus group (Westaway et al., 1985) and causes acute encephalitis associated with damage to the central nervous system (Oyanagi et al., 1969) . Its epidemiological and structural aspects have been extensively reviewed (Monath, 1986; Rosen, 1986; Umenai et al., 1985; Chambers et al., 1990) . Passive administration of anti-JEV antibodies has been shown to confer protection against JEV in mice (Kimura- Kuroda & Yasui, 1988) . However, the significance of this protection is unclear since the neurovirulence of JEV and yellow fever virus can be enhanced by the administration of virus-specific antibodies (Barrett & Gould, 1986; Gould & Buckley, 1989) . The observation that adoptive transfer of immune T cells can protect mice from a subsequent challenge with JEV (Mathur et al., 1983) and the report that JEV-immunized normal nude (nu)/+BALB/c mice were effectively protected from a subsequent intracerebral challenge with JEV whereas athymic nu/nu BALB/c mice were not (Miura et al., 1990) suggests that T cells play a role in host defence against JEV. It is not yet known whether T cells confer protection by cytotoxic T lymphocyte (CTL) generation in addition to antibody synthesis (Mori et al., 1970) . These findings indicate the importance of further studies on cell-mediated immune responses against these viruses. Major histocompatibility complex (MHC)-restricted CTLs have been raised against West Nile virus (WNV)-infected and dengue virus-infected cells (Kesson et al., 1987 (Kesson et al., , 1988 Bukowski et at., 1989; Pang et al., 1988) . Both these viruses are flaviviruses.
However, there has been no report so far describing the generation of CTLs that specifically recognize JEV by immunization with JEV-infected cells. One of the reasons for this could be the difficulty in obtaining cells that are not only permissive to JEV infection and replication but are also syngeneic with responder mice (Hill et at., 1992) . Several H-2 defined cell lines were therefore examined for their ability to support JEV infection and replication. Utilizing the JEV-infectible cell lines JEV-specific CTLs were generated by the immunization of BALB/c mice with virus-infected xenogeneic cells followed by in vitro stimulation with virus-infected syngeneic macrophage turnout cells. These effector cells are specific for JEV-infected syngeneic cells and are Lyt-2.2 +. WNV-infected syngeneic targets were, however, recognized to a limited extent. In addition these CTLs recognized JEV-infected (H-2KkD a) neuro-0001-1752 © 1994 SGM blastoma cells and were also stimulated by them. We further demonstrate that these CTLs can block the release of infectious viral particles from JEV-infected target cells in vitro.
Methods
Mice. BALB/c (H-2 d) mice were obtained from the Indian Institute of Science colony and 6-to 8-week-old male mice were used for all studies.
Stimulator and target cells. P388D1, P815 and L1210 cells (DBA/2 mouse origin, H-2d), Sp2/0, RAW 264.7, BALB. 3T3 (BALB/c mouse origin, H-2'~), YAC-1, Neuro 2a (A/J mouse origin, H-2KkDa), EL-4 (C57BL/6 mouse origin, H-2 b) and L929 (C3H mouse origin, H-U) cells were cultured at 37 °C in RPMI 1640 medium supplemented with antibiotics and 5% fetal calf serum (FCS: Gibco) in a 5% CO 2 atmosphere. All cell lines were obtained from the National Facility for Animal Tissue and Cell Culture Collection (Pune, India). Cells were used during their logarithmic growth phase in all experiments.
Virus growth and mfectton of cell lines. JEV strain P20778, an isolate from human brain (Kedarnath et al., 1986) , was routinely grown in C6/36 cells grown to confluence in MEM supplemented with 10 % FCS (Gibco). Infected C6/36 cell culture supernatants were used as the source of virus in all our studies. WNV mosquito isolate G22886 was obtained from the National Institute of Virology, Pune, India, and grown in the brains of suckling mice. Ten percent brain homogenate was used to infect target cells. Virus titration was carried out by plaquing on porcine kidney (PS) cells as described (Gould & Clegg, 1985) with modifications. Briefly, PS monolayers established in 24-well Linbro plates (Costar) were adsorbed with 10-fold dilutions of viruscontaining fluid for 60 rain at 37 °C after which they were washed and overlaid with Eagle's MEM containing 2 % FCS and 0.55 % agarose. After 3 days of incubation at 37 °C, cells were stained with 0.5 % crystal violet and the plaques were counted. Duplicate or triplicate experiments were routinely done along with titration of a standard virus-containing fluid. The assay was optimized on the basis of the titre, size and clarity of plaques. Both C6/36 and PS cells are established cell lines derived from mosquito and porcine kidney respectively (Mason, 1989; Shah & Gadkari, 1987) and are widely utilized for establishing JEV growth and maintenance.
Cell lines were infected through exposure to JEV-containing C6/36 cell culture supernatants for 1 h at 37 °C followed by removal of the inoculum and subsequent culture in RPMI 1640 medium supplemented with 2 % FCS. The volume of inoculum was adjusted to obtain the required infectious virus unit:cell ratio. Virus replication was monitored by measuring the release of infectious virus into the culture supernatants as described above and by immunofluorescence staining of cells using monoclonal antibodies specific to the JEV envelope antigen. JEV-specific monoclonal antibody clones 112 and 503 as well as the flavivirus cross-reactive clone 301 were provided as a kind gift from Dr J. Kimura-Kuroda and their specificities have been described previously (Kimura-Kuroda & Yasui, 1988) . Immunofluorescence analysis of JEV-infected cells was carried out by staining acetone-fixed cell smears with JEV-specific monoclonal antibody followed by FITCconjugated goat anti-mouse IgG. JEV-specific fluorescence was observed using a Leitz fluorescence microscope. The percentage of infected cells was calculated after observing a total of 4000 to 6000 cells in five or six different fields, The values are represented as mean+_s.D. Infected cell smears stained with normal goat serum followed by secondary antibody served as controls. Uninfected cells were also stained for comparison. Both were negative for JEV-specific fluorescence, In vivo primary immunizations and secondary in vitro stimulations. Six-to eight-week-old male BALB/c mice were generally immunized intraperitoneally (i.p.) twice with 3 x 106 JEV-infected PS cells followed by 1 × 107 JEV-infected Sp2/0 cells at 3-day intervals on days 0, 3 and 6 respectively. The JEV-infected PS and Sp2/0 cells used were obtained 24 h after being infected at an m.o.i, of 1 and 10 p.f.u, per cell respectively. The mice were sacrificed on day 10 and 1 x 107 primed splenocytes (responder cells) were cultured in vitro in 24-well Linbro plates with 2 x 105 virus-infected syngeneic stimulator cells. P388D1 stimulator cells were prepared by infecting cells with JEV at an m.o.i. of 10 p.f.u, per cell for 24 h followed by irradiation at 3000 rads using a *°Co radiation source. Effector cells were generated at 37 °C in a 5 % CO 2 atmosphere by in vitro culture in RPMI 1640 medium supplemented with antibiotics, 5 x 10 4 u-2-mercaptoethanol, 0.32 mg/ml L-glutamine, 0"1 mg/ml non-essential amino acids, 0"12 mg/ml sodium pyruvate and 5 % FCS. When Sp2/0 and Neuro 2a cells were used as stimulator cells, they were infected with JEV for 24 h and 6 h at an m.o.i, of 10 and 0.1 p.f.u, per cell respectively before irradiation at 3000 rads. The number of virus units used to infect the cell lines and the times at which they were harvested were standardized to ensure that maximum possible infection at optimal cell viabilities was achieved.
CTL assays and target cell preparations. Various numbers of effector cells generated in mixed lymphocyte cultures (MLC) were incubated with 2 x 104 51Cr-labelled virus-infected or uninfected cells for 5 h at 37 °C after briefly centrifuging them together in 96-well V-bottom plates at 100 g for 4 min. Target cells were prepared by incubating them with 200 gCi of Na251CrOa (BRIT, Bombay, India) for 60 nfin and subsequently washing them to remove free 51Cr. Virus infection of target cells was carried out as mentioned previously. P388D1 and Neuro 2a cells were harvested 48 h and 12 h respectively after being infected with JEV at an m.oa. of 1 p.f.u, per cell as above. The conditions of viral infection were varied in initial experiments to optimize cell viability during SlCr labelling and release assays. At the end of the incubation period, a sample of cell-free supernatant was removed and the 51Cr released was counted in an LKB gamma counter. Triphcate and quadruplicate examinations were routinely included in all assays and the percentage lysis of target cells was calculated as [(c.p.m. released in the presence of effector cells-c.p.m, released due to spontaneous leakage)/(total c.p.m, released by 0.2% Triton X-100--c.p.m. released due to spontaneous leakage)] x 100.
Effector cell depletion studies. Anti-JEV effector cells or allogeneic CTLs were treated with anti-Thy-1 monoclonal antibody (clone NIMR-1, Sera-Lab. 1 : 800 dilution), anti-Lyt-2.2 monoclonal antibody [clone AD4 (15), Cedarlane, 1:5 dilution] or anti-L3T4 monoclonal antibody (clone YT8191.1.2, Sera-Lab, 1:200 dilution) at 37 °C for 15 min. The dilutions of anti Thy-1 and anti Lyt-2.2 were chosen based on manufacturers' recommendations and an assessment of their ability to deplete completely the CTL activity of allogeneic BALB/c (H-2 d) ant1 C57BL/6 (H-2 b) effector populations. After removal of unadsorbed antibody, cells were incubated at 37 °C for 30 rain with fivefold diluted guinea-pig serum that had been specially screened for low toxicity on spleen cells before being used as a source of complement. After washing, the cytotoxic activity of surviving cells was tested by incubating them with 2 x 104 SlCr-labelled target cells and assayed for 51Cr release as described above. Effector cells treated with guinea-pig serum alone or anti-mouse IgG antibody were used as controls.
Unlabelled target competmon studies. Unlabelled virus-infected or uninfected competitor cells at various concentrations were mixed with 2 x 104 SlCr-labelled P388DI target cells and the mixture was incubated with anti-JEV effector cells at 37 °C and monitored for 5aCr release as described above. Triplicate and quadruplicate samples were routinely assayed and the percentage lysis obtained at unlabelled to labelled target cell ratios of 5, 10, 20, 40 and 80 were calculated. Results are calculated as a percentage of control lysis obtained with SlCr-labelled JEV-mfected P388D1 cells in the absence of unlabelled competitor cells.
Results

Virus infection of stimulator and target cells
The successful generation of MHC-restricted virusspecific CTLs in BALB/c mice (H-2 d) requires the coculture of responder cells with virus-infected stimulator cells that are syngeneic to the responder mice. Hence different cell lines were examined for infection by JEV in vitro. Infection was monitored both by determining the amount of infectious virus release and immunofluorescence. As shown in Table 1 To compare the actual number of viral particles produced by these cell lines, the infectious virus released into culture supernatants was measured by plaquing on PS ceils. All cell lines showing positive immunofluorescence were also found to support viral replication. All other cell lines tested (P815, L1210, BALB.3T3, EL-4) including BALB/c splenocytes, thymocytes and peritoneal macrophages were neither significantly positive for virus-specific immunofluorescence nor had the ability to support virus production (data not shown).
In vivo and in vitro priming requirements
In order to develop a proper immunization protocol for producing anti-JEV effectors, we initially injected BALB/c mice i.p. with JEV-infected syngeneic (Sp2/0, RAW 264.7, H-2d), allogeneic (L929, H-U), xenogeneic (PS) cells or 1 x 107 p.f.u, of JEV in the form of infected mouse brain homogenate or infected C6/36 cell culture supernatant. Ten days after immunization, primed spleen cells were cultured in vitro with JEV-infected P388D1 (H-2 a) stimulator cells. Results of representative examples only are shown in Table 2 . In vitro stimulation without in vivo priming did not generate effectors that significantly lysed infected P388D1 target cells. Since the overall virus-specific lysis obtained was low when single immunizations were used, mice were subjected to multiple immunizations with the JEV-infected cell lines described above followed by secondary stimulation in vitro with JEV-infected P388D1 cells. As shown in Table 2 , when BALB/c mice were injected i.p. twice with JEV-infected PS cells followed by a further injection with JEV-infected Sp2/0 cells at 3 day intervals, this served to prime mice for generation of anti-JEV effector ceils to the optimum extent (Table 2 , experiment 5). Immunization alone without in vitro secondary stimulation, however, failed to generate any JEV-specific effectors. All other multiple immunization protocols that utilized RAW 264.7 and L929 cells also resulted in the generation of effector cells that specifically lysed JEV-infected P388D1 target cells. It was observed that either the lysis of uninfected target cells was higher or that the percentage specific lysis of infected target cells was lower. Based on the observation that xenogeneic PS cells were able to prime for an ant±viral CTL response, BALB/c mice were injected i.p. twice with JEV-infected PS cells and once with JEVinfected Sp2/0 cells for all other studies. The splenocytes obtained from such mice were stimulated in vitro with JEV-infected P388D1 cells.
Specific±O, of effectors for syngeneic JEV-infected stimulator and target cells
Since BALB/c (H-2d)-derived responders were stimulated by P388D1 (DBA/2-derived) cells with minor region disparity, this suggests that anti-JEV effectors were induced only in the presence of minor region disparity. We have hence studied the ability of JEVinfected RAW 264.7 and Sp2/0 cells to act as in vitro stimulators during the generation of anti-JEV effector cells. RAW 264.7 is a macrophage cell line and Sp2/0 is a hybridoma cell line derived from BALB/c mice and these are therefore completely syngeneic to the BALB/cderived responder spleen cells. As shown in Fig. 1 (c) , culture in vitro of such primed splenocytes with JEVinfected RAW 264.7 cells stimulated production of effector cells that could recognize JEV-infected P388D1 cells specifically. The use of infected Sp2/0 cells instead of infected P388D1 cells as stimulators also resulted in effectors that exhibited specific lysis of infected P388D1 target cells although the extent of lysis was low (Fig.  1 a) . Similarly, anti-JEV effectors generated using the optimal protocol also lysed infected Sp2/0 cells in a virus-specific manner although the percentage specific lysis of infected Sp2/0 cells was substantially lower than that of infected P388D1 target cells (Fig. 1 b) . The extent of lysis of uninfected P388D1 cells was found to be similar to that obtained when using YAC-1 target cells suggesting that virus-specific lysis was not due to natural killer cell activity.
The cross-reactivity of effector cells towards another flavivirus was determined by examining their ability to lyse P388D1 cells previously infected with WNV. As shown in Table 3 , 30 % of WNV-infected P388D1 target cells were lysed at an effector to target (E:T) ratio of 80: 1, whereas 52 % of JEV-infected P388D1 target cells were lysed at the same E:T ratio. However, P388DI cells were not lysed in a virus-specific manner when infected with an unrelated virus such as bovine rinderpest virus 4.1_+0"7 45"0±2.0 27"3 ±0"9 ND 20:1 2"7±0"4 30"3 ±0"9 18"7±0"5 ND 10:1 1"1 +0"1 23"3+0"7 11"0+0"8 ND 80:1 23±3"2 72"0±4"1 ND 26+1"1 40:1 12± 1"8 64"0 ± 2"8 ND 17±0"8 20:1 14_+1.3 58.5±4.1 ND 10± 1"4 10:1 6±3'2 29"0-t-1"3 ND 5±3"1 * Fifty-eight percent of cells were positive for JEV-specific immunofluorescence.
"~ Under these conditions 7 x 10 ~ p.f.u, of WNV was released per 1 x 106 cells into culture supernatant at 48 h after infection as assayed by plaquing on PS cells.
:~ P388D1 cells were infected with rinderpest virus (RPV) at anm.o.i. of 20 p.f.u, per cell and used as targets at 36 h after infection. Immunofluorescence analysis using antiserum specific for RPV showed 56 % of cells positive for fluorescence.
§ ND, Not determined. (paramyxovirus) although 56 % of cells were found to be positive for immunofluorescence when stained with rabbit antiserum specific for rinderpest virus. The virus stock and antiserum were obtained as a gift from Dr M. S. Shaila and Dr V. D. Josh±, Indian Institute of Science, Bangalore, India. In a separate experiment neither the JEV-infected allogeneic L929 cells (H-2 k) nor the JEVinfected xenogeneic PS cells were lysed by anti-JEV CTLs although more than 85 % of cells were found to be positive for JEV-specific immunofluorescence as tested by clone 503 monoclonal antibody.
Phenotypic characterization of anti-JEV effector cells
The cell surface phenotype of anti-JEV effector cells that were generated was characterized by depletion of T cells or Lyt-2.2 + cells from the effector cell population. As shown in Table 4 , both Thy-1 + and Lyt-2.2 + cell depletion resulted in reduced lysis of JEV-infected P388D1 cells. Also, addition of anti-Lyt-2.2 + mono- clonal antibody (ATCC TIB 210) alone to anti-JEV effector cells during "51Cr release assays completely inhibited lysis of target cells. This antibody inhibits lysis mediated by MHC class I-restricted Lyt-2.2 + cells even in the absence of complement (McCarthy & Singer, 1989; Sarmiento et al., 1980) . However, depletion of L3T4 + cells by incubating effector cells with anti-L3T4 monoclonal antibody followed by complement or B cell depletion using anti-mouse IgG and complement had no effect on specific lysis of infected target cells.
H-2K~D a neuroblastoma cells are lysed by anti-JEV CTLs
Since JEV replication was high in Neuro 2a cells and JEV predominantly infects the central nervous system, the ability of this neuroblastoma cell line to be lysed by anti-JEV CTLs was examined. No specific lysis of these cells was observed at 0 and 6 h post-infection, as shown in Fig. 2(a the same E:T ratio. Uninfected Neuro 2a cells were not lysed, suggesting that the CTLs specifically recognized JEV-infected cells. Since only virus-infected macrophage cell lines were used to generate CTLs in all the above studies, we examined the ability of JEV-infected neuroblastoma cells to stimulate the generation of anti-JEV CTLs. As shown in Fig. 2(b) , co-culture of primed mouse splenocytes with JEV-infected Neuro 2a cells resulted in the generation of effector cells that specifically lysed JEV-infected P388D 1 cells but not uninfected cells. However the lytic ability of these effector cells (24 % at an E:T of 28: 1) was lower (Fig. 2 b) than the lyric ability of effector cells generated by coculture of responder cells with JEV-infected P388D 1 cells (43 % at an E: T of 20: 1) (Fig. 2a) .
Unlabelled target competitive inhibition studies
The specificity of anti-JEV effector cells generated in primed BALB/c mice was further analysed by examining the competitive inhibition effects of unlabelled target cells added during the assay. As shown in Fig. 3(a) addition of unlabelled JEV-infected P388D1 cell competitors significantly inhibited the lysis of labelled JEVinfected P388D1 target cells even at an unlabelled to labelled target cell ratio of 10: 1. However, addition of unlabelled infected RAW 264.7, Sp2/0 and Neuro 2a cell competitors inhibited lysis of labelled JEV-infected P388D1 cells only at higher unlabelled to labelled target cell ratios (Fig. 3 b, c and d) .
Anti-JEV effector cells inhibit virus production
Lysis of cells by CTLs could lead to release of virus already formed before the lytic event, leading to further infection of neighbouring cells. The ability of virusspecific CTLs to mediate protection in vivo would, therefore, depend also on their ability to prevent further release of infectious viral particles efficiently. Therefore we examined virus production from JEV-infected cells in continuous cell cultures with antiviral CTLs. Since +lCr-labelled P388D 1 target cells were lysed maximally at 48 h after JEV infection, P388D1 cells infected with JEV for 48 h were harvested, washed and further cultured with anti-JEV effector cells, which were generated as mentioned previously. As shown in Fig. 4 (a) virus production in infected P388D1 cells that were infected with JEV for 48 h and then washed and recultured progressively increased, reaching a maximum at 48 h after reculture (96 h after infection). Relatively few virus particles were produced in cultures, however+ when CTLs were added. Similarly, incubation of P388D1 cells that were infected with JEV for 24 h and then washed and recultured with antiviral CTLs also blocked virus production (Fig. 4b) . Inhibition of virus production was apparent only at 12 h after the addition of CTLs. The effect of the addition of antiviral CTLs to P388D1 cells 1 h after JEV infection followed by continuous culture for a further period of 48 h was then examined. As shown in Fig. 4 (c) , whereas virus production progressively increased in normal cultures reaching a maximum after 48 h, substantial . In a parallel 5 h 51Cr release assay these anti-JEV effector cells exhibited a range of 33 to 36 % lysis of JEV-infected P388D1 targets at the same E:T ratio. Cell-free supernatants collected from cultures at different time points were assayed for infectious virus released by plaquing on PS cells. Owing to wide differences in viral titres observed in the two cell lines (Table 1) inhibition of virus production was seen only at 24 h after antiviral CTL addition. Since JEV is neurotropic, a similar experiment was carried out with infected Neuro 2a cells and results are shown in Fig. 4(d) . Antiviral CTLs blocked further virus release 18 h after addition to these cells. It should be noted that the residual increase in viral titres occurring up until 18 h after CTL addition could be due to the relatively lower lysis of infected Neuro 2a cells by anti-JEV effector cells as compared to infected P388D1 cells that was observed in ~lCr release assays,
Discussion
A variety of humoral and cellular effector mechanisms facilitate host defence against viral infections (Allan & Doherty, 1986; Gajdosova et al., 1981) . Similarly T cell responses of helper and cytotoxic types occur both in humans and mice infected with flaviviruses (Hill et al., 1992; Kulkarni et al., 1991) . Human CD8 + and CD4 + cytotoxic T cell responses to dengue virus-infected cells have been reported Rothman et al., 1989) . CTL responses to another flavivirus, WNV, have also been demonstrated. While this manuscript was in preparation the priming of CBA/H mice with JEV in vivo and in vitro to generate effector cells that lysed macrophages infected with WNV was reported (Hill et al., 1992) . However, these workers were unable to infect syngeneic macrophages with JEV. Hence it was not known whether these effector cells could have lysed JEVinfected syngeneic target cells. This needs to be determined since JEV does not share complete amino acid identity with the sequences of WNV and Kunjin viruses (Coia et al., 1988) . As a prerequisite for the generation of anti-JEV CTLs we screened a number of cell lines for their ability to support JEV replication. Utilizing these permissive cell lines (P388D1, L929, Sp2/0 and RAW 264.7) several protocols were designed for the purpose of generating anti-JEV effector cells. Immunization of mice in our initial experiments with JEV-containing brain homogenate or C6/36 culture supernatant samples resulted in a CTL response upon secondary & vitro stimulation with JEV-infected P388D 1 cells. However, these effector cells exhibited higher nonspecific lysis of uninfected target cells (data not shown) possibly owing to the presence of extraneous proteins in the brain homogenate or FCS in the cell culture supernatants used for immunization. Priming of the immune system to MHC class I-mediated reponses requires intracellular replication of the virus. Therefore the use of infected cells as immunizing agents could prime the immune system to produce antiviral CTLs more efficiently, as has been shown by Green et al. (1979) who reported that immunization of mice with virusproducing allogeneic cell lines facilitated the generation of CTLs raised against endogenous AKR/Gross murine leukaemia viruses that are otherwise weakly immunogenic.
All immunization protocols were performed with JEVinfected cells rather than with purified virus to facilitate the generation of CTLs not only against virus-specific proteins but also against viral proteins such as prM and NS1 which are present only in infected cells but not in mature viral particles (Russell et al., 1980; Chambers et al., 1990) . In the event of poor surface expression of viral determinants, successful #1 vivo priming may occur due to simultaneous cell surface display of both virusassociated determinants and allo-antigens (Green et al., 1979) . In addition to the strong primary responses raised against allogeneic MHC antigens, efficient recognition of HLA xenoantigen structures has also been reported (Kievits et al., 1990) . Hence we examined the ability of infected virus-allogeneic and xenogeneic cells to prime mice. The CTLs generated in this study were not only JEV-specific but also specific for self H-2 antigen (Table  3) . Although mice were primed with infected xenogeneic cells, neither infected allogeneic L929 cells nor infected PS cells were lysed to any significant extent. This may be due to expansion of H-2-restricted, virus-specific precursor CTL populations upon secondary in vitro culture with JEV-infected P388D 1 cells. The mechanism whereby xenogeneic cells prime BALB/c mice to generate a selfrestricted antiviral CTL response is as yet unknown. However, fixation of PS cells with paraformaldehyde did not alter their ability to prime BALB/c mice when injected i.p. demonstrating that this effect was not due to virus release in vivo (data not shown). PS cells, being of non-murine origin, could also lead to stronger stimulation in vivo by the stronger generation of lymphokines. In addition, we observed that these anti-JEV effector cells lyse WNV-infected P388D1 target cells (Table 3) . Lysis values for 51Cr-labelled infected P388D1 target cells reached a maximum of approximately 80 % (Fig.  1 b, c) although cells positive for JEV envelope-specific immunoftuorescence reached a maximum value of 50 % at the time of CTL assay. This could be accounted for if either antigenic specificity of CTLs might be different from that of the antibody or alternatively that the effectors efficiently recognized extremely low concentrations of viral antigenic determinants not expressed on the cell surface.
The positive lysis observed in Neuro 2a ceils suggests the absence of H-2 class II-restricted CTLs since the class II allotype of Neuro 2a is H-U (Morgeaux et al., 1989) . In addition, T cell depletion studies also demonstrate that the effector cells generated were Lyt-2.2 +, and hence class I-restricted. The observation that infected Neuro 2a cells were recognized by anti-JEV effector cells (Fig. 2) suggests that the viral antigens were at least in part recognized in association with H-2D ~ antigens. Although Neuro 2a cells were more permissive to JEV as compared with P388D1 cells the lysis of P388D1 cells was greater than that of Neuro 2a cells. This could be due to the recognition of H-2K~-associated viral antigen in P388D1 cells in addition to H-2Dd-associated antigen. Both uninfected as well as infected P388D1 and Neuro 2a cells were found to be positive for H-2 class I antigen expression when analysed for class I-specific immunofluorescence (data not shown).
Our unlabelled target competition experiments demonstrate qualitative differences in the recognition of different JEV-infected syngeneic target cells by CTLs. This could be due to (i) preferential association of antigenic peptides with either H-2K or D antigen in different cell lines and (ii) expression of the CTLrecognizable viral determinants may vary over time and from cell line to cell line (Mullbacher & King, 1989) .
Addition of anti-viral CTLs to infected Neuro 2a and P388D 1 cell cultures effectively blocked further release of virus particles. Although only 33 to 36 % lysis of target cells was observed in 5~Cr release assays, the reason for the virtually complete blockage of virus release from infected cells (Fig. 4) at a corresponding E:T ratio is unknown. This could also be due to the inactivation of existing virus particles by granule exocytosis from antiviral CTLs as suggested earlier (Anderson et al., 1985) . Alternatively liberation of cytokines may also block virus release. It has been reported that WNV infection can upregulate expression of H-2 class I antigens in primary astrocyte cultures (Young et al, 1989) . This observation along with our data that antiviral CTLs can inhibit ongoing virus production in JEVinfected syngeneic P388D1 and Neuro 2a cells will assist in future examinations of the potential of such CTLs to protect mice from lethal intracerebral challenge by virus.
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